Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application

The aim of this study was to develop an intranasal in situ thermo-gelling meloxicam-human serum albumin (MEL-HSA) nanoparticulate formulation applying poloxamer 407 (P407), which can be administered liquid state into the nostril, and increase resistance against mucociliary clearance by sol-gel transition on nasal mucosa, as well improve drug absorption. Nanoparticle characterization showed that formulations containing 12–15% w/w P407 met requirements administration. Z-average (in range 180–304 nm), narrow polydispersity index (PdI, from 0.193 0.328), zeta potential (between ?9.4 ?7.0 mV) hypotonic osmolality (200–278 mOsmol/L) MEL-HSA nanoparticles predict enhanced absorption through mucosa. Based rheological, muco-adhesion, release permeability studies, 14% (MEL-HSA-P14%) considered optimized formulation, allows MEL blood–brain barrier-specific lipid fraction. Cell line studies no cell damage after 1-h treatment with MEL-HSA-P14% RPMI 2650 human endothelial cells’ moreover, permeation (four-fold) observed comparison pure MEL. Overall, promising for overcoming challenges delivery.